Membranous Nephropathy Market Research Report - Forecast to 2027

Membranous Nephropathy Market Research Report: Type (Primary, Secondary) Treatment (Conservative Therapy, Non-Immunosuppressive Therapy) Diagnosis (CT Scan, Urine Test, Blood Test) End User (Hospitals, Specialty Centers) – Global forecast till 2027

ID: MRFR/Pharma/4304-HCR | | Region: Global | 105 pages

Please note that the assessment period of the report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario


Membranous nephropathy is a kidney disorder. It is an autoimmune disorder which can occur by itself or in conjunction with several other diseases. Membranous nephropathy is one of the most common causes of the nephrotic syndrome. Membranous nephropathy can be caused due to various factors such as any autoimmune disease, use of certain medications such as nonsteroidal anti-inflammatory drugs, and exposure to certain infection such as hepatitis B, hepatitis C, and syphilis.


The global membranous nephropathy market is majorly driven by the growing prevalence of kidney disorders, rising older population leading to rise in the patient population, the rise in hepatitis affected infections, and growing mass young population inclined towards a sedentary lifestyle. Additionally, government funding’s, rising demand for novel treatment and market players offering advanced products are likely to drive the market.


According to the United Nations, in 2017 approximately over 962 million population were aged over 60 and above globally. United Nations has also estimated that by 2050, the number of older population is likely to reach 425 million. Additionally, according to WHO, around 71 million people are affected with hepatitis C globally. This rising aging population and rising hepatitis cases are likely to propel the growth of the global membranous nephropathy market. Factors that are likely to hamper the growth of the market are the lack of awareness regarding treatment.


The global membranous nephropathy market is expected to grow at a CAGR of 3.5% during the forecast period.


Figure: Global Membranous Nephropathy Market, by Region, 2016 (%)


 Membranous Nephropathy Market


Source: World Health Organization, Centers for Disease Control and Prevention, expert interview, annual report, white paper, company presentation, market research future analysis


 Intended Audience



  • Pharmaceutical Manufacturers and Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Research Methodology:


 Membranous Nephropathy Methodology


Source: World Health Organization, Centers for Disease Control and Prevention, Expert Interview, Annual Report, White Paper, Company Presentation, and Market Research Future Analysis


Segments  


The global membranous nephropathy market is segmented on the basis of type, treatment, diagnosis, and end-user.


On the basis of type, the market is segmented into primary and secondary.


On the basis of treatment, the market is segmented into conservative therapy, non-immunosuppressive therapy, and immunosuppressive therapy.


On the basis of diagnosis, the market is segmented into urine test (urinalysis), blood test, glomerular filtration rate test, an antinuclear antibody test, kidney ultrasound or Computed Tomography (CT), kidney biopsy, an anti-PLA2R antibody test, and others.


On the basis of end-user, the market is segmented into research centers, hospitals, and specialty centers.


Regional Analysis


The North American membranous nephropathy market is a growing market. On a regional basis, the Americas region is segmented into North America and South America. North America is segmented into the U.S. and Canada. Increasing number of hepatitis affected the population, along with rising older population is likely to drive the market. Additionally, growing healthcare expenditure and rising demand for technologically advanced treatments and products along with the rising government support are likely to enhance the growth of the membranous nephropathy market in North America.


Europe is the second largest market and holds a healthy share in the global membranous nephropathy market. The European market is expected to grow at a healthy CAGR during the forecast period owing to the availability of newer and advanced treatment facilities and rising skilled medical professionals along with the growing need for a better healthcare scenario. Furthermore, rising older population, along with growing inclination towards sedentary lifestyle are driving the growth of the membranous nephropathy market.


Asia Pacific is expected to be the fastest growing market. Increasing prevalence of chronic diseases and infections are the major drivers for the market growth. China is the fastest growing region owing to an increasingly older population and rising patient population. Rising awareness regarding health and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and rise in the standard of living are driving the growth of the membranous nephropathy market in the Asia Pacific region.


The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access, and availability of treatment facilities. In the Middle East, the United Arab Emirates is the largest market owing to the rise in healthcare development and rising demand for availability of specialty care centers.


Key Players       


Some of the key players in the membranous nephropathy market are Abbvie, Inc., Allergan Plc., Amgen Inc., Astrazeneca Plc, F. Hoffmann-La Roche Ltd, and FibroGen, Pfizer Inc., among others.



Frequently Asked Questions (FAQ) :


Major diagnostic tools used for Membranous Nephropathy include CT scan, urine test, and blood test.

Global Membranous Nephropathy Market is expected to exhibit a strong 3.5% CAGR over the forecast period from 2020 to 2027.

The growing prevalence of kidney diseases is the major driver for the Membranous Nephropathy Market.

The Americas hold a dominant 45% share in the Global Membranous Nephropathy Market.

Leading players in the Membranous Nephropathy Market include Abbvie, Allergan, and Pfizer, among others.

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Membranous Nephropathy Market, by Type

6.1 Introduction

6.2 Primary Membranous Nephropathy

6.2.1 Market Estimates & Forecast, 2020–2027

6.3 Secondary Membranous Nephropathy

6.3.1 Market Estimates & Forecast, 2020–2027

7. Global Membranous Nephropathy Market, by Diagnosis

7.1 Introduction

7.2 Urine Test (Urinalysis)

7.2.1 Market Estimates & Forecast, 2020–2027

7.3 Blood Tests

7.3.1 Market Estimates & Forecast, 2020–2027

7.4 Glomerular Filtration Rate Test

7.4.1 Market Estimates & Forecast, 2020–2027

7.5 Antinuclear Antibody Test

7.5.1 Market Estimates & Forecast, 2020–2027

7.6 Kidney Ultrasound or Computed Tomography (CT)

7.6.1 Market Estimates & Forecast, 2020–2027

7.7 Kidney Biopsy

7.7.1 Market Estimates & Forecast, 2020–2027

7.8 Anti-PLA2R Antibody Test

7.8.1 Market Estimates & Forecast, 2020–2027

7.9 Others

7.9.1 Market Estimates & Forecast, 2020–2027

8. Global Membranous Nephropathy Market, by Treatment

8.1 Introduction

8.2 Conservative Therapy

8.2.1 Market Estimates & Forecast, 2020–2027

8.3 Non-Immunosuppressive Therapy

8.3.1 Market Estimates & Forecast, 2020–2027

8.4 Immunosuppressive Therapy

8.4.1 Market Estimates & Forecast, 2020–2027

9. Global Membranous Nephropathy Market, by End-U.S.er

9.1 Introduction

9.2 Hospitals

9.2.1 Market Estimates & Forecast, 2020–2027

9.3 Specialty Centers

9.3.1 Market Estimates & Forecast, 2020–2027

9.4 Research Centers

9.4.1 Market Estimates & Forecast, 2020–2027

10 Global Membranous Nephropathy Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 U.K.

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12 Company Profiles

12.1 Abbvie, Inc

12.1.1 Company Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Allergan Plc

12.2.1 Company Overview

12.2.2 Product Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Amgen Inc

12.3.1 Company Overview

12.3.2 Product Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 AstraZeneca Plc

12.4.1 Company Overview

12.4.2 Product/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 F. Hoffmann-La Roche Ltd

12.5.1 Company Overview

12.5.2 Product Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 FibroGen

12.6.1 Company Overview

12.6.2 Product Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 Pfizer Inc

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Pharmaceutical Industry

14 Appendix

LIST OF TABLES

Table 1 Membranous Nephropathy Industry Synopsis, 2020–2027

Table 2 Global Membranous Nephropathy Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Global Membranous Nephropathy Market, by Region, 2020–2027, (USD Million)

Table 5 Global Membranous Nephropathy Market, by Treatment, 2020–2027, (USD Million)

Table 6 Global Membranous Nephropathy Market, by Diagnosis, 2020–2027, (USD Million)

Table 7 Global Membranous Nephropathy Market, by End-U.S.er, 2020–2027, (USD Million)

Table 8 North America Membranous Nephropathy Market, by Treatment, 2020–2027, (USD Million)

Table 9 North America Membranous Nephropathy Market, by Diagnosis, 2020–2027, (USD Million)

Table 10 North America Membranous Nephropathy Market, by End-U.S.er, 2020–2027, (USD Million)

Table 11 U.S. Membranous Nephropathy Market, by Treatment, 2020–2027, (USD Million)

Table 12 U.S. Membranous Nephropathy Market, by Diagnosis, 2020–2027, (USD Million)

Table 13 U.S. Membranous Nephropathy Market, by End-Users, 2020–2027, (USD Million)

Table 14 Canada Membranous Nephropathy Market, by Treatment, 2020–2027, (USD Million)

Table 15 Canada Membranous Nephropathy Market, by Diagnosis, 2020–2027, (USD Million)

Table 16 Canada Membranous Nephropathy Market, by End-Users, 2020–2027, (USD Million)

Table 17 South America Membranous Nephropathy Market, by Treatment, 2020–2027, (USD Million)

Table 18 South America Membranous Nephropathy Market, by Diagnosis, 2020–2027, (USD Million)

Table 19 South America Membranous Nephropathy Market, by End-Users, 2020–2027, (USD Million)

Table 20 Europe Membranous Nephropathy Market, by Treatment, 2020–2027, (USD Million)

Table 21 Europe Membranous Nephropathy Market, by Diagnosis, 2020–2027, (USD Million)

Table 22 Europe Membranous Nephropathy Market, by End-Users, 2020–2027, (USD Million)

Table 23 Western Europe Membranous Nephropathy Market, by Treatment, 2020–2027, (USD Million)

Table 24 Western Europe Membranous Nephropathy Market, by diagnosis, 2020–2027, (USD Million)

Table 25 Western Europe Membranous Nephropathy Market, by End-Users, 2020–2027, (USD Million)

Table 26 Eastern Europe Membranous Nephropathy Market, by Treatment, 2020–2027, (USD Million)

Table 27 Eastern Europe Membranous Nephropathy Market, by diagnosis, 2020–2027, (USD Million)

Table 28 Eastern Europe Membranous Nephropathy Market, by End-Users, 2020–2027, (USD Million)

Table 29 Asia Pacific Membranous Nephropathy Market, by Treatment, 2020–2027, (USD Million)

Table 30 Asia Pacific Membranous Nephropathy Market, by diagnosis, 2020–2027, (USD Million)

Table 31 Asia Pacific Membranous Nephropathy Market, by End-Users, 2020–2027, (USD Million)

Table 32 Middle East & Africa Membranous Nephropathy Market, by Treatment, 2020–2027, (USD Million)

Table 33 Middle East & Africa Membranous Nephropathy Market, by diagnoses, 2020–2027, (USD Million)

Table 34 Middle East & Africa Membranous Nephropathy Market, by End-Users, 2020–2027, (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Membranous Nephropathy Market

Figure 3 Segmentation Market Dynamics for Membranous Nephropathy Market

Figure 4 Global Membranous Nephropathy Market Share, by Treatment 2020

Figure 5 Global Membranous Nephropathy Market Share, by Diagnosis 2020

Figure 6 Global Membranous Nephropathy Market Share, by End-User, 2020

Figure 7 Global Membranous Nephropathy Market Share, by Region, 2020

Figure 8 North America Membranous Nephropathy Market Share, by Country, 2020

Figure 9 Europe Membranous Nephropathy Market Share, by Country, 2020

Figure 10 Asia Pacific Membranous Nephropathy Market Share, by Country, 2020

Figure 11 Middle East & Africa Membranous Nephropathy Market Share, by Country, 2020

Figure 12 Global Membranous Nephropathy Market: Company Share Analysis, 2020 (%)

Figure 13 Abbvie, Inc: Key Financials

Figure 14 Abbvie, Inc: Segmental Revenue

Figure 16 Abbvie, Inc: Geographical Revenue

Figure 17 Allergan Plc: Key Financials

Figure 18 Allergan Plc: Segmental Revenue

Figure 19 Allergan Plc: Geographical Revenue

Figure 20 Amgen Inc.: Key Financials

Figure 21 Amgen Inc.: Segmental Revenue

Figure 22 Amgen Inc. Geographical Revenue

Figure 23 FibroGen: Key Financials

Figure 24 FibroGen: Segmental Revenue

Figure 25 FibroGen: Geographical Revenue

Figure 26 GlaxoSmithKline plc: Key Financials

Figure 27 GlaxoSmithKline plc: Segmental Revenue

Figure 28 GlaxoSmithKline Plc. Geographical Revenue

Figure 29 Ardelyx, Inc.: Key Financials

Figure 30 Ardelyx, Inc.: Segmental Revenue

Figure 31 Ardelyx, Inc.: Geographical Revenue

Figure 32 Astellas Pharma Inc.: Key Financials

Figure 33 Astellas Pharma Inc.: Segmental Revenue

Figure 34 Astellas Pharma Inc.: Geographical Revenue